: Trulieve, Ascend Wellness CEOs chart multi-state growth


While earnings from Trulieve and Ascend Wellness contained some negative surprises, CEOs see richer returns ahead for 2022 amid multi-state rollouts.

Biotech Stock News: NervGen Pharma (TSXV: NGEN) Receives Approval to Proceed to the Final Dose Cohort in Phase 1 Clinical Trial of NVG-291 and Reports Q1 2022 Results

Previous article

: Robinhood stock rockets after FTX CEO Bankman-Fried invests nearly $650 million, saying he doesn’t plan to make changes

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in News